A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany)
-
Published:2024-08
Issue:
Volume:19
Page:100512
-
ISSN:2590-1362
-
Container-title:Vaccine: X
-
language:en
-
Short-container-title:Vaccine: X
Author:
Kowalzik Frank,
Teschner Daniel,
Mesquita Margarida,
Jensen Christian,
Schreiner Daniel,
Kronfeld KaiORCID,
Tubic-Grozdanis Marija,
Cheatham-Seitz Darline,
Hettich Franziska,
Quintini Gianluca,
Schoenborn-Kellenberger Oliver,
Codó Paula,
von Eisenhart-Rothe Philipp,
Mann PhilippORCID,
Oostvogels Lidia,
Gehring Stephan
Reference14 articles.
1. WHO. WHO COVID-19 vaccine tracker. Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed on 22/03/2023).
2. The spike protein of SARS-CoV — a target for vaccine and therapeutic development;Du;Nat Rev Microbiol,2009
3. Viral targets for vaccines against COVID-19;Dai;Nat Rev Immunol,2021
4. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease;Goldblatt;Immunol Rev,2022
5. The humoral response and antibodies against SARS-CoV-2 infection;Qi;Nat Immunol,2022